Stephen V. Liu, MD, of the Georgetown University School of Medicine and Georgetown’s Lombardi Comprehensive Cancer Center in Washington, DC, joined Lung Cancers Today to discuss the results of the phase 2 eNRGy study, which were recently published in The New England Journal of Medicine. The study demonstrated that zenocutuzumab had efficacy in patients with advanced NRG1 fusion–positive cancer, including patients with non–small cell lung cancer (NSCLC). ...

Lung Cancers Today
A new medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and more.
Advertisement
It is the "first and only neoadjuvant-only immuno-oncology therapy" to show a significant OS benefit in this setting.
A multicenter study that included 21,062 patients who were seen from 2009-2021 in South Korea provided key insights.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The 12-member board will guide the guide the patient-driven organization’s research and strategic priorities.
The study is comparing ivonescimab plus platinum-based chemotherapy with tislelizumab plus platinum-based chemotherapy.
Mara B. Antonoff, MD, FACS, discusses what could be on the horizon for surgery in stage IV lung cancer.
The bispecific antibody, which recently received FDA accelerated approval, showed a response rate of 29% in NSCLC.
Dr. Merritt shares new thoracic surgery research insights for patient selection in sublobar resection for early-stage NSCLC.
The recommendation is based on results from the phase 3 ADRIATIC trial.
The study aims to confirm safety and efficacy findings from the phase 2 QUILT 3.055 trial.
Advertisement